Astellas Pharma (ALPMY) Stock Price, News & Analysis

Company Overview

Astellas Pharma Inc. is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes. Astellas also develops and commercializes products through collaborations with other pharmaceutical and biotechnology companies, including PADCEV for bladder cancer.

Astellas was established in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical and is headquartered in Tokyo, Japan. It operates research, development and commercial activities across Japan, the United States, Europe and other international markets. Naoki Okamura serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $14.89 to $15.29
• 50-Day Range: $13.09 to $15.47
• 52-Week Range: $10.03 to $17.35
• Volume: 59,863 shs
• Average Volume: 156,679 shs
• Market Capitalization: $27.48 billion
• P/E Ratio: 11.56
• Dividend Yield: 1.91%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Astellas Pharma Stock Analysis - MarketRank™

Astellas Pharma scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Astellas Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Astellas Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -5.71%

Earnings Growth

Earnings for Astellas Pharma are expected to decrease by -5.71% in the coming year, from $1.40 to $1.32 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Astellas Pharma is 11.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Astellas Pharma is 11.53, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.72.

Price to Book Value per Share Ratio

Astellas Pharma has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Astellas Pharma has been sold short.

Short Interest Ratio / Days to Cover

Astellas Pharma has a short interest ratio ("days to cover") of 0.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Astellas Pharma has recently decreased by 64.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Astellas Pharma pays a meaningful dividend of 1.89%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Astellas Pharma does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Astellas Pharma is 22.14%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Astellas Pharma will have a dividend payout ratio of 21.97% next year. This indicates that Astellas Pharma will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Astellas Pharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Astellas Pharma this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for ALPMY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Astellas Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

Astellas Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 4/27/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ALPMY
• CIK: 1446390
• Web: www.astellas.com
• Phone: (133) 244-3000
• Fax: N/A
• Employees: 14,099
• Year Founded: 1923

Profitability

• EPS (Trailing Twelve Months): $1.31
• Trailing P/E Ratio: 11.53
• Forward P/E Ratio: 10.82
• P/E Growth: N/A
• Net Income: $1.83 billion
• Net Margins: 16.01%
• Pretax Margin: 17.60%
• Return on Equity: 25.79%
• Return on Assets: 12.87%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 1.20
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: $14.21 billion
• Price / Sales: 1.93
• Cash Flow: $2.21 per share
• Price / Cash Flow: 6.87
• Book Value: $6.36 per share
• Price / Book: 2.38

Miscellaneous

• Outstanding Shares: 1,809,660,000
• Free Float: N/A
• Market Cap: $27.42 billion
• Optionable: Not Optionable
• Beta: 0.08